1AD (1AD) News
Follow 1AD (1AD) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 2 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
AdAlta says Oribiotech customer deal validates its IRO manufacturing plan
AdAlta (ASX:1AD) says its automated IRO manufacturing strategy has gained commercial validation after Oribiotech secured a major long-term customer under a 10-year agreement worth up to US$120 million.
EQUITY | Sep 18, 2026, 03:02 AM UTC
M
AdAlta partner gets China approval for armored CAR-T mesothelioma therapy
Shanghai Cell Therapy Group, AdAlta’s co-development partner, received approval to provide BZDS1901 first-in-class armored CAR-T therapy to eligible patients with advanced mesothelioma under China’s special access scheme
GEOPOLITICS | Sep 02, 2026, 03:06 AM UTC